Expert consensus on diagnosis and treatment of renal cell cancer bone metastasis (2021 edition).

VernacularTitle:肾癌骨转移临床诊疗专家共识(2021版)
Collective Name:Genitourinary Oncology Committee of Chinese Anti-cancer Association
Publication Type:Journal Article
Keywords: Bone metastasis; Bone-modifying drugs; Kidney neoplasms; Multidisciplinary diagnosis and treatment
MeSH: Bone Neoplasms/drug therapy*; Carcinoma, Renal Cell/drug therapy*; Consensus; Humans; Kidney Neoplasms; Quality of Life
From: Chinese Journal of Oncology 2021;43(10):1007-1015
CountryChina
Language:Chinese
Abstract: Bone is a common metastatic site of renal cell carcinoma (RCC), with about 30% of metastatic RCC patients are suffering from bone metastasis. More than 70% of RCC patients with bone metastasis may experience skeletal related events (SREs), which may severely impair patients' quality of life and even shorten their survival time. Therefore, SREs prevention has become one of the treatment objectives of RCC bone metastasis. Bone-modifying agents are the basic treatment of bone metastases in addition to anti-tumor therapy. The treatment of RCC bone metastasis also requires multi-disciplinary team and individualized comprehensive treatment strategies. To standardize the diagnosis and treatment of RCC bone metastasis in China, the expert group of Genitourinary Oncology Committee, Chinese Anti-cancer Association has formulated the expert consensus for the reference of clinical practice, to improve the general therapeutic level of RCC with bone metastasis and benefit more patients.